Establishment of patient-derived tumor xenograft (PDTX) models using samples from CT-guided percutaneous biopsy

Abstract

This study aimed to investigate the feasibility of the establishment of a human cancer xenograft model using samples from computed tomography (CT)-guided percutaneous biopsy. Fresh tumor tissues obtained from 10 cancer patients by CT-guided percutaneous biopsy were subcutaneously inoculated into NOD-Prkdcem26Il2rgem26Nju (NCG) mice to establish human patient-derived tumor xenograft (PDTX) models. The formation of first and second generation xenografts was observed, and tumor volume was recorded over time. Tumor tissue consistency between the PDTX model and primary tumors in patients was compared using H&E staining and immunohistochemistry. Pharmacodynamic tests of clinically used chemotherapeutic drugs were conducted on second generation xenografts, and their effects on tumor growth and body weight were observed. CT-guided percutaneous biopsy samples were successfully collected from 10 patients with advanced cancers. The PDTX model was established in mice using tumor samples obtained from 4 cancer patients, including one small cell carcinoma sample, two adenocarcinoma samples, and one squamous cell carcinoma sample. The success rate was 40%. The obtained PDTX model maintained a degree of differentiation, and morphological and structural characteristics were similar to primary tumors. The pharmacodynamic test of chemotherapeutic drugs in the PDTX model revealed a therapeutic effect on tumor growth, as expected. CT-guided percutaneous biopsy samples can be effectively used to establish a PDTX model, and test these chemotherapy regimens.

c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis

“…Pathologic staging was performed in accordance to the current International Union against Cancer tumor-lymph node-metastasis classification. The patient-derived tumor xenograft (PDTX) experiments were performed as previously described 39 .…”

Establishment of a non-small-cell lung cancer-liver metastasis patient-derived tumor xenograft model for the evaluation of patient-tailored chemotherapy

“…The construction of metastatic PDTX model is constrained due to the impracticable surgery of advanced cancer patients. In such circumstances, CT-guided percutaneous lung biopsy may give another option [19], which is used to classify pathological tumor phenotype and to screen tumor-derived gene mutation available with targeting drugs. In the present study, a fresh biopsy of lung tumor tissues is used to ensure tumorigenesis, and further transplanted into NOD/SCID mice and Balb/c nu/nu mice.…”

“…Less time is needed to construct the PDTX F2 model when compared with the PDTX F1 model, which indicates increasing tumorigenesis and metastatic property. Successive cancer tissue transplants in immunocompromised mice are performed in the present study, which can maintain at least some aspects of the patient-derived tumors in hereditary characteristic (genetic alterations), growth microenvironment, response to chemotherapy [10,13,19,20]. Moreover, such a model also maintains the original tumor heterogeneity, representing a promising model for investigating specific cellular subpopulations [21].…”

Combination of Palbociclib and Erlotinib Exhibits Synergistic Antitumor Effect in Colorectal Cancer Patient-Derived Xenograft (PDX) Models

“…After the successful formation of CRC organoids, palbociclib, erlotinib, or their combination was added into the culture medium to evaluate their effects. For the PDX model, 4-5 weeks female immunode cient NCG mice [23] were used as the recipient of patient-derived CRC tissue. Fresh surgically resected CRC tissues from two CRC patients (P328 and P44)…”